HK Stock Movement | LAIKNA-B (02105) Surges Over 15%, Up 40% This Month Following BD Deal for LAE002

Stock News11-27

LAIKNA-B (02105) surged more than 15%, extending its monthly gain to over 40%. At the time of writing, the stock rose 15.38% to HK$16.95, with a turnover of HK$58.22 million.

The rally follows the company's recent business development (BD) deal for its breast cancer drug candidate LAE002 (afuresertib). On November 12, LAIKNA licensed the China rights for LAE002 to Qilu Pharmaceutical in a transaction worth RMB 2.045 billion. Additionally, LAIKNA is entitled to receive tiered sales royalties ranging from 10% to over 20%.

According to broker research, LAE002 is projected to achieve peak sales of around RMB 2 billion in China. Globally, its sales potential could mirror that of Capivasertib, which is expected to generate $700–800 million this year, with peak sales estimated at $1–2 billion.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1168384821?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-27 10:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168384821","market":"hk","top_or_hot":-1,"title":"HK Stock Movement | LAIKNA-B (02105) Surges Over 15%, Up 40% This Month Following BD Deal for LAE002","media":"Stock News","content":"<p>LAIKNA-B (02105) surged more than 15%, extending its monthly gain to over 40%. At the time of writing, the stock rose 15.38% to HK$16.95, with a turnover of HK$58.22 million.</p>\n<p>The rally follows the company's recent business development (BD) deal for its breast cancer drug candidate LAE002 (afuresertib). On November 12, LAIKNA licensed the China rights for LAE002 to Qilu Pharmaceutical in a transaction worth RMB 2.045 billion. Additionally, LAIKNA is entitled to receive tiered sales royalties ranging from 10% to over 20%.</p>\n<p>According to broker research, LAE002 is projected to achieve peak sales of around RMB 2 billion in China. Globally, its sales potential could mirror that of Capivasertib, which is expected to generate $700–800 million this year, with peak sales estimated at $1–2 billion.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | LAIKNA-B (02105) Surges Over 15%, Up 40% This Month Following BD Deal for LAE002</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | LAIKNA-B (02105) Surges Over 15%, Up 40% This Month Following BD Deal for LAE002\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-27 10:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LAIKNA-B (02105) surged more than 15%, extending its monthly gain to over 40%. At the time of writing, the stock rose 15.38% to HK$16.95, with a turnover of HK$58.22 million.</p>\n<p>The rally follows the company's recent business development (BD) deal for its breast cancer drug candidate LAE002 (afuresertib). On November 12, LAIKNA licensed the China rights for LAE002 to Qilu Pharmaceutical in a transaction worth RMB 2.045 billion. Additionally, LAIKNA is entitled to receive tiered sales royalties ranging from 10% to over 20%.</p>\n<p>According to broker research, LAE002 is projected to achieve peak sales of around RMB 2 billion in China. Globally, its sales potential could mirror that of Capivasertib, which is expected to generate $700–800 million this year, with peak sales estimated at $1–2 billion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1168384821","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168384821","pubTimestamp":1764210751,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"LAIKNA-B (02105) surged more than 15%, extending its monthly gain to over 40%. At the time of writing, the stock rose 15.38% to HK$16.95, with a turnover of HK$58.22 million. The rally follows the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02105":"来凯医药-B"},"translate_title":"港股走势|LAIKNA-B(02105)继BD交易LAE002后，本月飙升逾15%，升40%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02105":1},"content_text":"LAIKNA-B (02105) surged more than 15%, extending its monthly gain to over 40%. At the time of writing, the stock rose 15.38% to HK$16.95, with a turnover of HK$58.22 million.\nThe rally follows the company's recent business development (BD) deal for its breast cancer drug candidate LAE002 (afuresertib). On November 12, LAIKNA licensed the China rights for LAE002 to Qilu Pharmaceutical in a transaction worth RMB 2.045 billion. Additionally, LAIKNA is entitled to receive tiered sales royalties ranging from 10% to over 20%.\nAccording to broker research, LAE002 is projected to achieve peak sales of around RMB 2 billion in China. Globally, its sales potential could mirror that of Capivasertib, which is expected to generate $700–800 million this year, with peak sales estimated at $1–2 billion.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1168384821","isCrawlerRequest":true}